Science & Research
Chiropractic Study Shows Non-Surgical Recovery From Severe Disc Injuries
A new study published in the Journal of Contemporary Chiropractic demonstrates that non-surgical chiropractic care can effectively manage massive lumbar disc herniations, offering a conservative alternative to invasive surgical treatments.
Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference
Kairos Pharma Ltd. will present initial Phase 1 data for its ENV105 combination therapy targeting drug-resistant non-small cell lung cancer at the World Lung Cancer Conference, potentially addressing significant unmet medical needs in oncology treatment.
IBM and AMD Partner to Advance Quantum Computing Integration with High-Performance Systems
IBM and AMD have announced a collaboration to develop next-generation computing systems that integrate quantum and high-performance computing, potentially accelerating practical quantum applications.
Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Progress in Neuropsychiatric Treatments
Cybin Inc.'s participation in the Cantor Global Healthcare Conference underscores the company's advancing clinical programs for mental health disorders, including its Phase 3 CYB003 for major depressive disorder and Phase 2 CYB004 for generalized anxiety disorder, both of which hold significant potential to address unmet medical needs.
InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease
InFlectis BioScience and Aix Marseille Université have demonstrated that lead compound IFB-088 shows efficacy in animal models of axonal Charcot-Marie-Tooth disease type 2A, expanding its potential to address multiple CMT subtypes with no approved treatments.
New Research Reveals 62% of AFib Patients Unaware of Condition Before Diagnosis
A new American Heart Association study shows most atrial fibrillation patients were unaware of their condition before diagnosis, highlighting critical gaps in public awareness about this serious heart rhythm disorder that significantly increases stroke risk.
GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference
GeoVax Labs will showcase progress on its Mpox/smallpox, COVID-19, and cancer immunotherapy programs at the upcoming H.C. Wainwright conference, highlighting advancements in vaccine development and manufacturing capabilities.
Sigyn Therapeutics Expands Cardiovascular Disease Study to Target Lipoprotein Reduction
Sigyn Therapeutics plans a clinical feasibility study of its blood purification technology that could address cardiovascular disease in high-risk patients while potentially extending lives of end-stage renal disease patients and generating significant economic impact.
Study Links Self-Medicating with Cannabis to Increased Paranoia Risk
New research indicates that individuals using marijuana to cope with depression, anxiety, or pain face higher paranoia risks compared to recreational users, while licensed operators may help reduce associated stigma.
Study Links Head Injuries to Increased Brain Cancer Risk, Driving Treatment Research
A Mass General Brigham study of 75,000 patients reveals traumatic brain injuries elevate malignant brain tumor risk, highlighting the importance of ongoing treatment development by companies like CNS Pharmaceuticals Inc.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Calidi Biotherapeutics to Present RedTail Platform at H.C. Wainwright Global Investment Conference
Calidi Biotherapeutics will showcase its innovative RedTail platform at the H.C. Wainwright conference, highlighting its potential to revolutionize cancer treatment through systemic delivery of genetic medicines to metastatic sites.
IntegrateRNA Launches Custom Aminoacyl-tRNA Synthesis Service to Advance Protein Engineering Research
IntegrateRNA's new Aminoacyl-tRNA In Vitro Synthesis Service enables researchers to create custom proteins with non-canonical amino acids, potentially accelerating drug discovery and biotechnology development.
CD BioGlyco Expands Glycobiology Research Capabilities with Custom Glycoconjugate Synthesis Service
CD BioGlyco's new custom glycoconjugate synthesis service enables researchers to study glycan functions in cell recognition and immune responses, advancing biomedical research capabilities.
Creative Biolabs Advances Biopharmaceutical Innovation Through Glycobiology Expertise
Creative Biolabs is enhancing biopharmaceutical development through advanced glycoprotein engineering and polysaccharide analysis technologies that improve drug efficacy, safety, and stability.
Clene Inc. Advances Neurodegenerative Disease Treatment CNM-Au8® Toward Potential FDA Accelerated Approval
Clene Inc. is progressing its oral treatment CNM-Au8® for ALS and multiple sclerosis through late-stage clinical development, with key FDA meetings and regulatory catalysts potentially accelerating commercialization for patients with limited treatment options.
Zevra Therapeutics to Present New MIPLYFFA Data at International Congress, Including Best Poster Award Winner
Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol) at the International Congress of Inborn Errors of Metabolism, including a Best Poster award-winning presentation detailing its mechanism of action for treating Niemann-Pick disease type C, highlighting significant advancements in rare disease treatment.
Oncotelic Therapeutics Highlights Robust Oncology Pipeline and CEO's Patent Portfolio
Oncotelic Therapeutics showcases its clinical-stage oncology and immunotherapy pipeline, including multiple late-stage candidates and rare disease programs, while emphasizing CEO Dr. Vuong Trieu's extensive intellectual property contributions that underpin the company's competitive strategy.
New PREVENT Equations Transform Cardiovascular Risk Assessment and Personalize Hypertension Treatment
The American Heart Association's PREVENT equations provide more accurate cardiovascular disease risk predictions, enabling personalized treatment decisions for adults with high blood pressure while addressing concerns about overtreatment.
New Mathematical Index Aims to Eliminate Bias in College Football Rankings
Mike MacQuarrie introduces a bias-free Strength of Schedule Index that uses mathematical calculations to objectively rank college football teams based solely on on-field performance and opponent quality, potentially transforming how playoff teams are selected.
University of Utah Study Identifies Mechanism Behind Blood Clot Risk in IBD Patients
New research from the University of Utah reveals why inflammatory bowel disease patients face elevated blood clot risks and suggests potential dual-treatment approaches that could address both clotting and inflammation.
MyBioSource Launches Validated Anti-CALB2 Antibody for Neuroscience Research
MyBioSource has introduced a validated sheep anti-rat calretinin polyclonal antibody that enables advanced research into calcium signaling, neuroprotection, and neurodegeneration across multiple species.
DEA Advances Psilocybin Rescheduling Petition to HHS for Scientific Review
The DEA's decision to forward psilocybin rescheduling for scientific review marks a significant regulatory shift that could expand medical access for veterans and palliative care patients while accelerating psychedelic research.
Nerve Damage Identified as Unexpected Cause of Cancer Immunotherapy Resistance
A multinational research team has discovered that cancer-induced nerve damage contributes to immunotherapy resistance, potentially opening new treatment avenues for patients.
New Particle Discovery Could Overcome Key Quantum Computing Stability Challenge
Researchers have identified a previously overlooked particle that may solve quantum computing's critical stability problems, potentially enabling the development of reliable large-scale quantum machines.
CNS Pharmaceuticals CEO Outlines Glioblastoma Treatment Strategy and Market Opportunities in Podcast Interview
CNS Pharmaceuticals CEO John Climaco discussed the company's progress in developing novel brain cancer treatments and expanding into aggressive cancers like triple-negative breast cancer with brain metastases during a recent BioMedWire podcast appearance.
Soligenix Advances Rare Disease Pipeline with Key Clinical Milestones Expected Through 2026
Soligenix Inc. reports significant progress in its late-stage rare disease treatments, including pivotal Phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies that could transform care for underserved patient populations.
7-HOPE Alliance Defends Legality and Safety of 7-OH, Challenges Kratom Association Claims
The 7-HOPE Alliance asserts that 7-hydroxymitragynine is lawful and scientifically supported, countering claims by kratom associations while highlighting potential medical benefits and harm reduction value.
Cybin Receives Australian Approval for Phase 3 Study of Psychedelic-Based Depression Treatment
Cybin Inc. has secured Australian regulatory approval to conduct its EMBRACE Phase 3 clinical trial of CYB003, a novel deuterated psilocin analog, marking a significant advancement in developing next-generation treatments for major depressive disorder.
NRx Pharmaceuticals' Depression Treatment Receives FDA Fast Track Designation
NRx Pharmaceuticals' NRX-100 received FDA Fast Track designation for treating suicidal ideation, potentially expanding its market to 13 million U.S. adults and offering a novel approach targeting neuroplasticity in depression treatment.